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In Brief
Inflammation mediates tissue repair but
can be hijacked to promote
tumorigenesis. Hoste et al. demonstrate
that HMGB1 delays regeneration and
drives tumor formation in skin by
recruitment and priming of neutrophils.
These data indicate that therapies
targeting HMGB1 or NET formation might
be relevant in chronic and diabetic wound
treatment.
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Regenerative responses predispose tissues to
tumor formation by largely unknown mechanisms.
High-mobility group box 1 (HMGB1) is a danger-
associated molecular pattern contributing to inflam-
matory pathologies. We show that HMGB1 derived
from keratinocytes, but not myeloid cells, delays
cutaneous wound healing and drives tumor forma-
tion. In wounds of mice lacking HMGB1 selectively
in keratinocytes, a marked reduction in neutrophil
extracellular trap (NET) formation is observed. Phar-
macological targeting of HMGB1 or NETs prevents
skin tumorigenesis and accelerates wound regener-
ation. HMGB1-dependent NET formation and skin
tumorigenesis is orchestrated by tumor necrosis
factor (TNF) and requires RIPK1 kinase activity.
NETs are present in the microenvironment of kerati-
nocyte-derived tumors in mice and lesional and
tumor skin of patients suffering from recessive
dystrophic epidermolysis bullosa, a disease in
which skin blistering predisposes to tumorigenesis.
We conclude that tumorigenicity of the wound
microenvironment depends on epithelial-derived
HMGB1 regulating NET formation, thereby estab-
lishing a mechanism linking reparative inflammation
to tumor initiation.Cell Repor
This is an open access article under the CC BY-NINTRODUCTION
Danger-associated molecular patterns (DAMPs) activate the im-
mune system upon injury and have key roles in cancer by either
promoting inflammation or by driving the cytotoxic anti-tumor
host response (Hernandez et al., 2016). However, the specific
contribution of individual DAMPs in these processes are still
enigmatic. High-mobility group box 1 (HMGB1) is a multifunc-
tional protein that serves as a transcriptional regulator in the nu-
cleus but upon secretion acts as a DAMP, potently activating
inflammation (Scaffidi et al., 2002). HMGB1 performs its cytokine
function by binding to various receptors, the best documented
being RAGE (receptor for advanced glycation end products)
and TLR-4 (Toll-like receptor 4) (Hori et al., 1995; Yang et al.,
2010). Increased levels of circulating HMGB1 have been shown
to amplify the inflammatory responses that regulate tumor pro-
gression, invasion, and metastasis (Kang et al., 2013), but the
importance of HMGB1 in initiating neoplastic responses is
largely unknown. In skin, we previously showed that flagellated
bacteria can trigger TLR-5 activation in leukocytes, inducing
the upregulation of cutaneous HMGB1 expression levels and
the promotion of wound-induced tumorigenesis (Hoste et al.,
2015). Although HMGB1 has previously been implicated in tissue
regeneration (Huebener et al., 2015; Straino et al., 2008; Tirone
et al., 2018), the molecular mechanisms through which this
DAMP mediates wound repair and neoplastic events in skin
are still unknown.
Chronic and acute wounding predisposes tissues to tumor for-
mation (Arwert et al., 2012). In skin, this association is remarkablyts 29, 2689–2701, November 26, 2019 ª 2019 The Author(s). 2689
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
clear in patients suffering from recessive dystrophic epidermoly-
sis bullosa (RDEB), a rare genetic cutaneous blistering disorder.
Skin of RDEB patients constantly undergoes injury and repair,
predisposing the epidermis to squamous cell carcinoma (SCC)
formation (Fine et al., 2009). We previously demonstrated that
HMGB1 is abundantly secreted in SCC-associated skin of
RDEB patients (Hoste et al., 2015). Moreover, levels of circu-
lating HMGB1 have been shown to correlate with RDEB disease
severity (Petrof et al., 2013). Neutrophils are the first immune
cells recruited to wounded skin, where they can form neutrophil
extracellular traps (NETs), enabling neutrophils to fight patho-
gens (Belaaouaj et al., 1998; Brinkmann et al., 2004). NET forma-
tion is characterized by the release of neutrophil chromatin deco-
rated with antimicrobial peptides in order to trap and potentially
kill pathogens. Although being an important antimicrobial de-
fense mechanism, NETs can also induce tissue damage, as is
the case in diabetic conditions, where neutrophils are primed
to form NETs, thereby delaying cutaneous wound healing (Me-
negazzo et al., 2015; Wong et al., 2015). Since NETs have also
been shown to impact on a plethora of diseases, including
asthma and arthritis (Jorch and Kubes, 2017; Khandpur et al.,
2013; Toussaint et al., 2017), and have been observed in the
microenvironment of various tumor types (Demers et al., 2016),
inhibiting NET formation might be an interesting therapeutic
strategy to treat disease. One important cytokine that has been
implicated in neutrophil priming is tumor necrosis factor (TNF)
(Yuo et al., 1991), which is also important for chemical- and
wound-induced skin carcinogenesis (Hoste et al., 2015; Moore
et al., 1999), implicating a role for TNF in mediating NET forma-
tion downstream of HMGB1 release.
Here, we tested the hypothesis that a sole DAMP, namely
HMGB1, impacts on pathological cutaneous remodeling and tu-
mor initiation. We could demonstrate a crucial role for epithelial-
derived HMGB1 in regenerative and neoplastic inflammation and
show that keratinocyte-specific HMGB1 primes neutrophils for
NET formation in full-thickness skin wounds, resulting in delayed
cutaneous wound closure and pro-tumorigenic signaling via TNF
and RIPK1 kinase signaling. These findings identify epithelial-
derived HMGB1 as a crucial molecule mediating tumorigenicity
of the wound microenvironment and suggest that HMGB1
neutralization or inhibition of NET formation may have potential
as a therapeutic strategy to prevent skin cancer and accelerate
cutaneous wound healing responses.
RESULTS
Keratinocyte-Specific HMGB1 Delays Wound Healing
and Promotes Skin Tumor Formation
In order to understand the in vivo function of HMGB1 as a DAMP
in cutaneous regenerative and neoplastic responses, we selec-
tively deleted HMGB1 in keratinocytes or monocytes/macro-
phages by crossing HMGB1 ‘‘floxed’’ mice (Huebener et al.,
2015) to mice expressing keratin-5 Cre (Tarutani et al., 1997) or
lysozyme M Cre (Clausen et al., 1999), respectively (Figures
S1A and S1B). Neither keratinocyte-specific HMGB1 knockout
(DKer HMGB1) mice nor myeloid-specific HMGB1 knockout
(Dmyelo HMGB1) mice displayed overt phenotypes. However,
when subjected to full-thickness skin wounding, healing rates2690 Cell Reports 29, 2689–2701, November 26, 2019were markedly accelerated in DKer HMGB1mice relative to litter-
mate HMGB1fl/fl (Cre negative) control mice (Figure 1A; Fig-
ure S1C). Interestingly, wound healing rates were indistinguish-
able between mice lacking HMGB1 in myeloid cells and
control littermates (Figure S1D). The accelerated wound healing
rates observed in DKer HMGB1 skin were not due to cell-auton-
omous keratinocyte effects, as primary keratinocytes in culture
showed faster healing effects in scratch-wound assays in
HMGB1-proficient versus HMGB1-deficient cultures (Fig-
ure S1E). HMGB1 is upregulated in various chronically inflamed
conditions (Degryse et al., 2001; Taniguchi et al., 2003); there-
fore, we next investigated wound healing responses in trans-
genic mice expressing a constitutively active MAP-kinase kinase
1 (MEK1) in differentiating keratinocytes (InvEE mice). These
mice exhibit chronic skin inflammation, allowing the study of
wound healing responses in a pathological skin context (Hobbs
et al., 2004). Upon skin wounding, InvEE mice lacking HMGB1
in keratinocytes closed their wounds markedly faster than
HMGB1-proficient InvEE mice (Figure 1B; Figure S1F). In
contrast, myeloid-cell-specific deletion of HMGB1 in InvEE
mice did not result in altered wound closure rates (Figure S1G).
Together, these data indicate that HMGB1 derived from
keratinocytes, but not myeloid cells, plays an important role in
reparative cutaneous inflammation.
HMGB1 has a context-dependent role in either promoting
tumorigenesis by triggering chronic inflammation or in protecting
from tumor development by eliciting immunogenic cell death
(Hernandez et al., 2016; Kang et al., 2013). To unravel the func-
tion of HMGB1 in cutaneous tumor initiation, we subjected InvEE
mice lacking HMGB1 in either keratinocytes or in myeloid cells to
wound-induced tumor formation. InvEE mice develop tumors at
sites of full-thickness skin wounding with an incidence of 50%
(Arwert et al., 2010). Strikingly, DKer HMGB1 mice were
completely protected from wound-induced tumor formation
(Figure 1C), while Dmyelo HMGB1 mice were equally sensitive
to InvEE papillomagenesis (Figure S1H). Given that HMGB1
has important roles in the nucleus where it mediates the assem-
bly of transcription factor complexes (Park et al., 2003; West
et al., 2004), we tested wound healing rates and skin tumorigen-
esis in the presence of Box A, an HMGB1 antagonist that pre-
vents HMGB1 binding to its receptors (Kokkola et al., 2003). In
agreement with the faster wound healing rates observed in
DKer HMGB1 mice (Figure 1B), accelerated wound closure was
also observed in InvEE mice that were intradermally injected
with Box A at time of wounding and during early stages of repair
(Figure 1D), and subsequent wound-induced tumor formation
was strongly reduced upon Box A treatment (Figure 1E).
Additionally, we intradermally injected mice with ethylpyruvate,
an established inhibitor of HMGB1 secretion (Dave´ et al., 2009;
Kim et al., 2016), and also observed a protective effect on InvEE
papillomagenesis (Figure 1F). In order to identify the receptor
through which HMGB1 mediates regenerative and tumorigenic
responses in skin, we next injected InvEE mice with antagonistic
agents against RAGE or TLR-4. Both TLR-4 as well as RAGE
neutralization resulted in enhanced wound closure in early
post-wounding stages (Figures S1I and S1J). In addition, treat-
ment with a monoclonal TLR-4 blocking antibody at the time of
wounding and during the early post-wounding stages
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Figure 1. Keratinocyte-Specific HMGB1 Delays Wound Healing and Promotes Skin Tumor Formation
(A and B) Wound healing dynamics of wild-type (HMGB1fl/fl, n = 17) and DKer HMGB1 (n = 14) mice (A) or InvEE HMGB1fl/fl (n = 24) and InvEE DKer HMGB1 (n = 15)
mice (B) after full-thickness wounding with an 8mmpunch biopsy (*p < 0.05; ***p < 0.001; ****p < 0.0001 between groups on respective days post-wounding; two-
way ANOVA with multiple comparisons).
(C) Incidence of papilloma formation in InvEE HMGB1fl/fl (n = 26) and InvEE DKer HMGB1 (n = 17) mice at site of wounding (**p = 0.002; Wilcoxon matched-pairs
signed rank test).
(D and E) Wound healing dynamics (D) and wound-induced tumor incidence (E) in InvEE HMGB1fl/fl (n = 12) and InvEE DKer HMGB1 (n = 12) mice intradermally
injected with PBS (vehicle) or with Box A (n = 8) at time of wounding and 12, 24, and 36 h post-wounding (**p = 0.0016; *p < 0.05; two-way ANOVA with multiple
comparisons).
(F) Wound-induced tumor incidence in InvEE HMGB1fl/fl mice intradermally injected with PBS (n = 16) or with ethylpyruvate (n = 7) at time of wounding and 12, 24,
and 36 h post-wounding (**p = 0.0039; Wilcoxon matched-pairs signed rank test).
(G) Wound-induced tumor incidence in InvEE HMGB1fl/fl mice intradermally injected with IgG (n = 10) or with a monoclonal TLR-4-inhibiting antibody (n = 10) at
time of wounding and 12, 24, and 36 h post-wounding (**p = 0.002; Wilcoxon matched-pairs signed rank test).
(H) Wound-induced tumor incidence in InvEE HMGB1fl/fl mice intradermally injected with PBS (n = 12) or with a RAGE antagonistic peptide (n = 8) at time of
wounding and 12, 24, and 36 h post-wounding (**p = 0.002; Wilcoxon matched-pairs signed rank test).
(I) Heatmap depicting mean expression of differentially expressed genes between InvEE HMGB1fl/fl and InvEE DKer HMGB1 keratinocytes.
(J) Incidence of papilloma formation in HMGB1fl/fl (n = 26) and DKer HMGB1 (n = 17) mice treated with DMBA and TPA (****p < 0.0001; Wilcoxon matched-pairs
signed rank test).
(K) Representative photographs of HMGB1fl/fl and DKer HMGB1 mice treated with DMBA and TPA at week 7, 10, and 14 after start of TPA treatment. Wound
healing data represent mean ± SEM.
See also Figure S1.completely protected InvEE mice from tumor development (Fig-
ure 1G). Treatment with a blocking peptide against RAGE also
protected InvEEmice fromwound-induced tumorigenesis, albeitto a lesser extent than treatment with a TLR-4 inhibiting antibody
(Figure 1H). RNA sequencing of sorted live integrin-alpha 6-pos-
itive keratinocytes obtained from InvEE DKer HMGB1 and InvEECell Reports 29, 2689–2701, November 26, 2019 2691
HMGB1-proficient mice indicated that HMGB1 is the sole cyto-
kine that is differentially expressed in both genotypes (Figure 1I;
Figure S1K; GEO: GSE138918).
In order to confirm our observations in the InvEE model of
wound-induced tumorigenesis in an independent skin tumor
model, we next subjected DKer HMGB1 and control littermates
to the two-stage chemically induced DMBA/TPA (7,12-dimethyl-
benz(a)anthracene and 12-O-tetradecanoylphorbol-13-acetate)
skin carcinogenesis model. In this model, skin cancer is induced
by exposure to a single dose of DMBA inducing oncogenic mu-
tations in HRas (initiation), followed by the repeated topical appli-
cation with the phorbol ester TPA (promotion) allowing mutagen-
ized cells to expand and form benign papillomas (Abel et al.,
2009). In agreement with the phenotype observed in wound-
induced tumorigenesis, mice lacking HMGB1 in keratinocytes
were also fully resistant to chemically induced tumor formation
(Figures 1J and 1K). Together, these data prove that keratino-
cyte-derived HMGB1 is a key DAMP that delays regenerative
wound healing responses and initiates neoplasia in chronically
inflamed skin.
Keratinocyte-Specific HMGB1-Deficient Mice Exhibit an
Exacerbated Cutaneous Response to TPA Treatment
HMGB1, in its function as a DAMP, has been characterized as a
potent pro-inflammatory mediator (Scaffidi et al., 2002; Wang
et al., 1999). To investigate whether the complete resistance of
DKer HMGB1 mice to chemically induced skin tumor formation
was due to reduced inflammation upon treatment with the pro-
inflammatory phorbol ester TPA, we examined the response of
DKer HMGB1 skin to topical TPA treatment. For this, DKer
HMGB1 and control littermate mice were repetitively treated
with TPA for a total of two to six applications, and skin was
collected 24 h after the last treatment (Figure 2A). Surprisingly,
DKer HMGB1 mice exhibited an exacerbated response to TPA
relative to HMGB1fl/fl control mice. After two topical TPA treat-
ments, a significantly higher increase in transepidermal water
loss (TEWL) was observed in DKer HMGB1 compared to control
mice. This response was even more pronounced in skin of DKer
HMGB1 mice treated six times with TPA (Figure 2B), indicating
a more severe skin barrier perturbation in the absence of kerati-
nocyte-derived HMGB1. In agreement, an increase in epidermal
thickness could be observed in skin of TPA-treated DKer HMGB1
mice relative to HMGB1fl/fl skin (Figures 2C and 2D), again indi-
cating a more severe tissue response to the pro-inflammatory
exposure to TPA in DKer HMGB1 skin relative to control skin.
To further discriminate between the effect of HMGB1 defi-
ciency in keratinocytes on DMBA-induced tumor formation
versus TPA-mediated tumor promotion, we subjected DKer
HMGB1 mice and control littermates to topical DMBA treatment
twice a week for 15 weeks. DKer HMGB1 mice were able to
mount a tumor-protective response to treatment with the carcin-
ogen alone, as tumor formation was strongly delayed upon
DMBA treatment (Figure 2E). However, in contrast to the
DMBA/TPA model, to which DKer HMGB1 mice were fully resis-
tant, tumors did arise in DKer HMGB1 mice treated with DMBA
alone, albeit far later and to fewer extent than in control litter-
mates (Figure 2E; Figure S2). In conclusion, given that DKer
HMGB1 mice exhibit an enhanced sensitivity to epidermal bar-2692 Cell Reports 29, 2689–2701, November 26, 2019rier perturbation upon repetitive treatment with the phorbol ester
TPA relative to their HMGB1fl/fl littermates, the tumor-protective
effect of HMGB1 ablation in keratinocytes does not result from a
reduced inflammatory response in these mice. However, our
data indicate that, depending on the type of epithelial damage,
keratinocyte-derived HMGB1 can either protect from epidermal
barrier perturbation or delay epithelial repair.
Epithelial-Derived HMGB1 Mediates Neutrophil
Infiltration and NET Formation in Skin Wounds
Neutrophils represent the first immune cell type that is recruited
to sites of injury. Interestingly, genes encoding for proteins
involved in neutrophil infiltration, such as the chemokines
Cxcl-2 and Ccl5 (RANTES), were significantly downregulated in
TPA-treated DKer HMGB1 mice relative to controls (Figure 3A).
These findings are in agreement with the reduced neutrophil infil-
tration seen in livers of acetaminophen-intoxicated hepatocyte-
specific HMGB1-deficient mice (Huebener et al., 2015).
Therefore, we tested whether neutrophil infiltration is altered in
wounds of mice lacking HMGB1 in keratinocytes. Indeed, as
shown by flow cytometric analysis, the total amount of neutro-
phils (CD45+ CD11b+ Ly6-G+ cells) that infiltrated the skin at
day 2 post-wounding was significantly lower in DKer HMGB1
compared to HMGB1fl/fl mice. In contrast, the total amount of
macrophages (CD45+ CD11b+ CD64+ cells) present in these
wounds did not differ between genotypes (Figures 3B and 3C).
Neutrophils can form extracellular traps, termed NETs, which
have been demonstrated to delay cutaneous wound healing re-
sponses (Wong et al., 2015). Given that we observed slower
wound closure in HMGB1fl/fl relative to DKer HMGB1 mice, we
analyzed whether the level of NET formation was reduced in
DKer HMGB1 wounds. Western blot analysis of skin wound
lysates showed prominent levels of citrullinated histone-3
(H3citr), an established marker for NET formation (Wong et al.,
2015; Toussaint et al., 2017), in HMGB1-proficient wounds,
whereas H3citr levels are barely detectable in DKer HMGB1
wounds at day 2 post-wounding (Figure 3D). NETs are defined
as neutrophilic extracellular DNA structures that colocalize with
granule-derived proteins and histones (Konig and Andrade,
2016; Boeltz et al., 2019). We performed immunofluorescent
staining of externalized DNA (DAPI) and assessed colocalization
with neutrophil elastase (NE) and H3citr. Confocal microscopy of
skin wounds of DKer HMGB1 and HMGB1fl/fl mice at early post-
wounding stage verified that NET formation was markedly
reduced in DKer HMGB1 wounds relative to control littermates
(Figure 3E). NETs were also observed in the tumor stroma of
wound-induced papillomas (Figure 3E) but were absent in un-
wounded DKer HMGB1 and HMGB1fl/fl mice. We also confirmed
the reduced level of histone-3 citrullination in neutrophils in DKer
HMGB1 skin wounds by flow cytometric quantification of live
neutrophils (CD45+ CD11b+ Ly6G+ cells) that stained for citrulli-
nated histone-3 in DKer HMGB1 and HMGB1fl/fl wounds at day 2
post-wounding (Figure 3F), although it should be stated that this
might be due to the reduced neutrophil infiltration observed in
DKer HMGB1 wounds. In conclusion, we could demonstrate
that keratinocyte-derived HMGB1 drives neutrophil infiltration
and NET formation in the early inflammatory response to full-
thickness skin wounding, thereby providing in vivo relevance of
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Figure 2. Keratinocyte-Specific HMGB1-Deficient Mice Exhibit an Exacerbated Response to TPA Treatment but Are Protected from DMBA-
Induced Carcinogenesis
(A) Experimental outline of TPA barrier perturbation protocol.
(B) Transepidermal water loss (TEWL) measurements were recorded 24 h after the last TPA treatment in HMGB1fl/fl (n = 8) and DKer HMGB1 (n = 14) mice
(****p < 0.0001; **p% 0.01; *p% 0.05; two-way ANOVA with multiple comparisons). Data represent mean ± SEM.
(C) Representative H&E-stained skin sections from HMGB1fl/fl and DKer HMGB1 mice that were subjected to six topical applications of TPA. Scale bars: 50 mm.
(D) Epidermal thickness was measured on H&E sections by ImageJ software; 10 measurements per field were performed for 3 fields per mouse. The thickness of
the epidermis was determined bymeasuring the distance from the basement membrane to the upper granular layer, excluding the cornified layers (****p < 0.0001;
***p = 0.0001; two-way ANOVA with multiple comparisons)). Data represent mean ± SEM.
(E) Tumor incidence (% of mice with one or more tumors) in HMGB1fl/fl (n = 14) andDKer HMGB1 (n = 11) mice treated with DMBA (**p = 0.002; Wilcoxonmatched-
pairs signed rank test).
See also Figure S2.HMGB1 acting as an upstream regulator of NET formation in skin
reparative inflammation.
Altered NET Formation Impacts on Wound-Induced
Tumorigenesis
The increased presence of NETs, delaying regenerative re-
sponses in skin, has recently been described in the context of
diabetes (Menegazzo et al., 2015; Wong et al., 2015). To investi-
gatewhether ablation of HMGB1 in keratinocytes affects wound-
induced tumor formation in conditions where neutrophils are
primed to NET formation, we subjected InvEE DKer HMGB1
and InvEE HMGB1fl/fl mice to streptozotocin (STZ)-induced
type 1 diabetes. STZ-challenged InvEE DKer HMGB1 diabetic
mice developed wound-induced tumor formation with an inci-
dence comparable to that of InvEE HMGB1fl/fl mice (Figure 4A),
indicating that in conditions that predispose neutrophils to NETformation, lack of epithelial-derived HMGB1 is no longer capable
of protecting the skin from tumorigenesis. This acquired sensi-
tivity to tumor development correlated with a less prominent
reduction in NET formation in wounded STZ-induced DKer
HMGB1 diabetic mice relative to wounded STZ-induced wild-
type diabetic mice, as demonstrated by western blotting for
H3citr levels (Figure 4B).
Digestion of NETs by DNase1 is sufficient to accelerate their
clearance by macrophages (Farrera and Fadeel, 2013). To
assess the causative involvement of NETs in cutaneous
wound-induced tumorigenesis, we next investigated whether in-
hibiting NETs by injecting DNase1 in InvEE mice could alter skin
tumor susceptibility. Indeed, injection of DNase1 in HMGB1-pro-
ficient InvEEmice at the time of wounding and in the initial stages
of wound healing resulted in a significant protection fromwound-
induced tumorigenesis (Figure 4C). In agreement, a significantCell Reports 29, 2689–2701, November 26, 2019 2693
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Figure 3. Keratinocyte-Derived HMGB1 Promotes Neutrophil Infiltration and NET Formation in Skin Wounds
(A) Relative levels of Rantes and Cxcl2 in epidermal lysates from TPA-treated HMGB1fl/fl and DKer HMGB1 skin. Data are depicted as the ratio of the mRNA
expression normalized to GAPDH and expressed as mean ± SEM (n = 4 per condition; **p = 0.0023; ***p = 0.0007; two-way ANOVA with multiple comparisons).
(B) Expression of CD64 and Ly6G by live CD45+ CD11b+ cells in skin wounds of HMGB1fl/fl and DKer HMGB1 mice.
(C) Absolute number of neutrophils and macrophages per skin wound at day 2 post-wounding in HMGB1fl/fl and DKer HMGB1 mice (n = 4 per group; *p = 0.0286;
Mann-Whitney test).
(D) Western blotting for citrullinated histone-3 (H3citr) on skin lysates of wounds at day 2 post-wounding in HMGB1fl/fl andDKer HMGB1mice. a-actin blot is shown
as loading control.
(E) Immunofluorescent labeling of neutrophil extracellular traps in skin wounds of HMGB1fl/fl and DKer HMGB1 mice and in wound-induced InvEE papillomas.
Paraffin sections were stained with antibodies against neutrophil elastase (NE; green), citrullinated histone-3 (H3citr; red), and DAPI (blue) as nuclear counterstain.
Scale bars: 100 mm. Dotted line represents epidermal-dermal boundary, asterisk indicates the wound edge, and boxed areas are magnifications as shown in the
boxes below and in the right panels.
(F) Presence of citrullinated histone-3 by live CD45+ CD11b+ Ly6G+ neutrophils in skin wounds of HMGB1fl/fl and DKer HMGB1 mice at day 2 post-wounding.
Absolute cell numbers of netting neutrophils per skin wound at day 2 post-wounding in HMGB1fl/fl and DKer HMGB1 mice (n = 4 per group; *p = 0.0286;
Mann-Whitney test).reduction in H3citr levels could be observed in wound lysates
after DNase1 treatment (Figure 4D). DNase1-injected mice also
closed their wounds markedly faster than control-injected InvEE
HMGB1fl/fl mice (Figure 4E), recapitulating the effect of HMGB1
ablation from keratinocytes. Interestingly, DNase 1 treatment
did not alter wound healing rates in DKer HMGB1 mice (Fig-
ure S3A). Of note, when epithelial damage was induced in InvEE
HMGB1-proficient mice by repetitive topical TPA treatment,
NETs could not be observed, and this type of injury did not result
in tumor formation in InvEEmice (Figure 4F; Figure S3B), demon-2694 Cell Reports 29, 2689–2701, November 26, 2019strating that the formation of NETs occurs only in specific condi-
tions of epithelial damage where it can drive tumor initiation.
HMGB1 Secretion and the Presence of NETs Coincide in
Wounded and Tumor-Bearing Skin
Our previous study demonstrated HMGB1 secretion in wound-
induced tumors in mice as well as in patients suffering from the
skin blistering disease RDEB (Hoste et al., 2015). Immunofluo-
rescent analysis revealed that HMGB1 is indeed highly upregu-
lated in the murine wound and tumor microenvironment from
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Figure 4. Altering NET Levels Impacts on Wound-Induced Tumorigenesis
(A) Wound-induced skin tumor incidence in STZ-challenged InvEE HMGB1fl/fl (n = 14) and InvEE DKer HMGB1 (n = 7) diabetic mice (ns, Wilcoxon matched-pairs
signed rank test).
(B) Western blotting for H3citr on skin lysates of wounds at day 2 post-wounding in normoglycemic and STZ-induced InvEE diabetic mice. a-actin blot is shown as
loading control.
(C)Wound-induced skin tumor incidence in InvEEHMGB1fl/fl mice injectedwith the NET inhibitor DNase 1 (n = 10) or with vehicle (PBS; n = 10) at time of wounding
and 12, 24, and 36 h post-wounding (**p = 0.002; Wilcoxon matched-pairs signed rank test).
(D) Western blotting for H3citr on skin lysates of wounds at day 2 post-wounding in InvEE DKer HMGB1 and control mice injected with DNase 1 or PBS (vehicle).
a-actin blot is shown as loading control.
(E) Wound healing dynamics of InvEE HMGB1fl/fl mice injected with DNase 1 (n = 11) or PBS (vehicle; n = 20) (****p < 0.0001; ***p = 0.0001; *p = 0.0415; two-way
ANOVA with multiple comparisons). Data represent mean ± SEM.
(F) Western blotting for H3citr on skin lysates of InvEE wounds at day 2 post-wounding or on lysates of TPA-treated skin of HMGB1fl/fl and DKer HMGB1 mice.
a-actin blot is shown as loading control.
See also Figure S3.control HMGB1fl/fl mice (Figure 5A). At day 2 post-wounding, we
observed the highest expression of HMGB1, both in the wound
stroma and in the adjacent epidermis (Figure 5A). ResidualHMGB1 staining in DKer HMGB1 epidermis is likely due to
HMGB1 expression by epidermal-resident immune cells. At
day 14 post-wounding, when re-epithelialization is largelyCell Reports 29, 2689–2701, November 26, 2019 2695
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Figure 5. Keratinocyte-Specific HMGB1 Mediates Regenerative and Tumorigenic Responses through TNF and RIPK1 Kinase Activity
(A) Paraffin sections of wounded and tumor-bearing InvEE HMGB1fl/fl and DKer HMGB1 skin were labeled with an anti-HMGB1 (red) antibody and counterstained
with DAPI (blue). Scale bars: 200 mm. dpw, days post-wounding. Arrowheads indicate the wound edge.
(B) Serum levels of HMGB1 in unwounded, wounded (d2pw, day 2 post-wounding), inflamed (InvEE), and InvEE mice bearing a wound-induced papilloma, as
assessed by ELISA (data represent mean ± SEM; nR 4 per condition; *p < 0.05; **p = 0.0012; Mann-Whitney test).
(C) Western blotting for HMGB1 and H3citr in skin lysates of unwounded (unw), and wounded (day 2, 6, and 8 post-wounding [pw]) InvEE HMGB1fl/fl (wild-type
[WT]) and DKer HMGB1 (knockout [KO]) mice. a-actin blot is shown as loading control.
(D) Concentration of TNF, IL-6, and IL-8 in serum of unwounded and wounded InvEE HMGB1fl/fl (WT) and DKer HMGB1 (KO) mice (data represent mean ± SEM;
nR 4 per condition; *p = 0.0317; Mann-Whitney test).
(E) Staining for TNF in wounded skin of InvEE HMGB1fl/fl and DKer HMGB1 mice at day 2 post-wounding. Scale bars: 50 mm.
(F) Wound-induced tumor incidence in InvEE HMGB1fl/fl mice intradermally injected with control IgG (n = 10) or TNF antagonistic antibody (n = 10) at time of
wounding and 12, 24, and 36 h post-wounding (**p = 0.002; Wilcoxon matched-pairs signed rank test).
(G) Western blotting for H3citr of day 2 post-wounding skin lysates of DKer HMGB1 and HMGB1fl/fl mice injected with a-TNF or a-IgG control antibodies. a-actin
blot is shown as loading control.
(H) Wound-induced skin tumor incidence in InvEE RIPK1WT/WT mice (n = 10) and InvEE RIPK1D138N/D138N mice (n = 10) (**p = 0.0039; Wilcoxon matched-pairs
signed rank test).
(I) Western blotting for H3citr of day 2 post-wounding skin lysates of InvEE RIPK1D138N/D138N and InvEE RIPK1WT/WTmice. a-actin blot is shown as loading control.completed, HMGB1 was still prevalent in wounded epidermis
and underlying stroma of HMGB1fl/fl mice, albeit to a lesser
extent than at day 2 post-wounding (Figure 5A). We further
observed higher levels of circulating HMGB1 levels in serum
from wounded mice compared to unwounded mice, and these
levels were even higher in serum of mice bearing skin tumors
(Figure 5B).2696 Cell Reports 29, 2689–2701, November 26, 2019The enhanced expression of HMGB1 in wounded skin was
next confirmed by western blotting on HMGB1fl/fl wound lysates
(Figure 5C), and a significantly reduced HMGB1 expression
could be confirmed in DKer HMGB1 skin wounds compared to
HMGB1fl/fl controls, demonstrating that keratinocytes are the
main source of HMGB1 during wound healing responses.
The prominent upregulation of HMGB1 during the early
post-wounding stage coincided with the highest expression of
H3citr (Figure 5C), implicating the formation of NETs as an early
and transient response to wounding. Interestingly, this early
post-wounding time point also represents the period when
most striking differences in wound healing responses are
observed between keratinocyte-specific HMGB1-proficient
versus -deficient mice (Figures 1A and 1B), indicating that
HMGB1 induces the release of NETs mainly in the initial stages
of wound healing, where they hamper regeneration and induce
neoplastic events.
Keratinocyte-Specific HMGB1 Mediates Regenerative
and Tumorigenic Responses through TNF and RIPK1
Kinase Activity
The proinflammatory cytokine TNFwas previously shown to pro-
mote chemically induced skin carcinogenesis (Moore et al.,
1999). To examine whether TNF mediates cutaneous regenera-
tive and tumorigenic responses downstream of HMGB1, we as-
sessed the levels of TNF in circulation of wounded and un-
wounded InvEE DKer HMGB1 mice relative to InvEE HMGB1-
proficient mice. Interestingly, a marked reduction in serum levels
of TNF was observed in wounded InvEE DKer HMGB1 mice rela-
tive to wounded InvEE HMGB1-proficient mice, while the levels
of other proinflammatory cytokines that are known to be involved
in skin carcinogenesis, such as IL (interleukin)-6 and IL-8 levels,
were not significantly altered betweenwoundedmice of both ge-
notypes (Figure 5D). In agreement, staining for TNF in cutaneous
wounds of InvEE DKer HMGB1 and control mice confirmed
reduced levels of TNF in wounds of mice lacking HMGB1 from
keratinocytes (Figure 5E). Finally, TNF-blocking antibodies
were injected in InvEE mice during the early post-wounding
stage, demonstrating a significant reduction in wound-induced
tumor formation compared to immunoglobulin G (IgG)-injected
control mice (Figure 5F). Western blotting of wound lysates of In-
vEE mice treated with and without TNF-blocking antibodies re-
vealed that H3citr levels were markedly reduced upon inhibition
of TNF (Figure 5G).
Recent work demonstrated that neutrophil Receptor-Interact-
ing-Protein Kinase-1 (RIPK1)-dependent necroptosis drives NET
formation (D’Cruz et al., 2018). Since TNF mediates RIPK1-
dependent apoptosis and necroptosis, we next investigated
whether wound-induced tumor formation depends on the kinase
function of RIPK1. For this, kinase-dead RIPK1 (RIPK1D138N)
mutant mice (Polykratis et al., 2014) were generated in the InvEE
genetic background, wounded, and monitored for skin papillo-
magenesis. InvEE RIPK1D138N mice were strongly protected
from wound-induced tumor development, demonstrating that
RIPK1kinase activity drives tumor formation (Figure 5H).Western
blotting of wounded skin lysates confirmed that citrullination of
histone-3 could not be observed in the absence of RIPK1 kinase
activity (Figure 5I). In conclusion, these data show that TNF and
subsequent RIPK1 activity act downstream of HMGB1 to
mediate NET formation and cutaneous tumor formation.
HMGB1 Secretion by Human SCC Cells Induces Cell
Death in Neutrophils
To investigate the relevance of enhanced HMGB1 expression for
NET formation and tumor induction in human skin, we analyzedskin sections from RDEB patients. Immunofluorescent analysis
of tissue sections obtained from RDEB patients demonstrated
the presence of NETs in RDEB lesional and SCC-associated
skin (Figure 6A), indicating that also in human skin, tumorige-
nicity of the wound microenvironment can be associated with
the occurrence of NETs. To further validate this hypothesis, we
analyzed the levels of secreted HMGB1 in the supernatant of
normal human keratinocyte cell lines versus SCC cells and could
observe a significant increase in HMGB1 release in SCC kerati-
nocytes versus normal keratinocytes (Figure 6B). Finally, live im-
aging of human neutrophils incubated with conditioned medium
of SCC versus normal keratinocytes revealed that neutrophil
death is accelerated upon incubation of the cells with condi-
tioned medium from SCC keratinocytes compared to condi-
tioned medium from normal keratinocytes (Figures 6C and 6D).
Together, these data identify a crucial role for epithelial-
derived HMGB1 in driving tumorigenicity of cutaneous wounds
by mediating the levels of NET formation by skin-infiltrating neu-
trophils in the early stages of wound repair. Upon pharmacolog-
ical inhibition of HMGB1 or NET formation in this early post-
wounding stage, mice close their cutaneous wounds faster
and are fully protected from keratinocyte-derived tumor
initiation.
DISCUSSION
Regenerative inflammation can induce neoplastic responses;
however, the molecular mechanisms underlying this association
are largely unknown. Our data identified a crucial role for kerati-
nocyte-derived HMGB1 in delaying cutaneous injury repair and
in driving tumorigenicity of cutaneous wounds by mediating
neutrophilic inflammation and NET formation in the early stages
of wound repair. Mice close their cutaneous wounds faster and
are fully protected from keratinocyte-derived tumor initiation
when HMGB1 release or NET formation are prevented in the
early post-wounding stage, suggesting that targeting HMGB1
or NETs might represent an interesting therapeutic avenue in
reducing wound-associated skin tumorigenesis.
Neutrophils represent the main cell type involved in the early
immune response during injury repair, where they can produce
NETs that have recently been implicated in various infectious
and inflammatory pathologies, including sepsis, liver injury,
atherosclerosis, and asthma (Hernandez et al., 2018; Papayan-
nopoulos, 2018; Toussaint et al., 2017; Warnatsch et al., 2015).
NETs can exert beneficial effects on wound healing due to their
bactericidal effects (Li et al., 2010; Brinkmann et al., 2004). How-
ever, antimicrobial factors such as neutrophil elastase and his-
tones can also damage epithelia and delay wound healing, as
is seen in conditions of excessive NET formation (Dovi et al.,
2003; Wong et al., 2015). Interestingly, the differences in wound
healing rates observed in DKer HMGB1 mice versus control mice
are most obvious during the time frame in which NET formation
occurs (Figures 1, 3, and 5).
TNF also has a predominant damaging activity in wound heal-
ing and skin tumorigenesis and is highly potent in priming neutro-
phils. Our observation that both TNF neutralization as well as ge-
netic inactivation of RIPK1 kinase activity protects mice from
wound-induced tumorigenesis indicates a crucial role forCell Reports 29, 2689–2701, November 26, 2019 2697
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Figure 6. HMGB1 Secretion by SCC Kerati-
nocytes Induces Neutrophilic Cell Death
(A) Immunofluorescent labeling of NETs in lesional
skin and SCCs of RDEB patients. Paraffin sections
were stained with antibodies against neutrophil
elastase (NE; green), citrullinated histone-3 (H3citr;
red), and DAPI (blue) as nuclear counterstain.
Scale bars: 50 mm.
(B) HMGB1 levels in supernatant of normal and
SCC human keratinocytes cultured in serum-free
conditions.
(C) Quantification of DNA externalization in
response to incubation with different conditioned
media as assessed by the ratio of Sytox Green
over Hoechst over time in live imaging of human
neutrophils (n = 6 per condition; ****p < 0.0001;
***p = 0.0001; two-way ANOVA with multiple
comparisons). Stimulation with recombinant TNF
and ionomycin was used as a positive control.
(D) DNA externalization as assessed by live im-
aging. Human neutrophils were stained with
Hoechst (blue) and DNA externalization was as-
sessed by SytoxGreen (green) positivity at the
indicated time points. Scale bar: 50 mm. Data
represent mean ± SEM.HMGB1 in driving TNF-RIPK1 signaling to skin carcinogenesis
(Figure 5). This is in line with a previous report indicating that anti-
body-mediated depletion of HMGB1 in a model of LPS-induced
lung inflammation dampened TNF-release and reduced NET
formation (Tadie et al., 2013).
Several molecular signaling pathways lead to the formation of
NETs (Konig and Andrade, 2016). One of these pathways was
initially described by Zychlinski et al. and shown to be dependent
on Nox2-mediated reactive oxygen species (ROS) production
(Brinkmann et al., 2004; Fuchs et al., 2007). An alternative and
presumably antagonistic pathway of chromatin extrusion by
neutrophils relies on calcium-dependent PAD4-mediated hyper-
citrullination (Wang et al., 2009). More recently, RIPK1-mediated
necroptosis (Desai et al., 2016) and gasdermin D-mediated
(Chen et al., 2018) pore formation were also shown to facilitate
the release of NETs. Our data identify a crucial role for NET for-
mation associated with protein hypercitrullination in skin wound-
ing and tumor initiation, consistent with an earlier study demon-
strating NET accumulation in diabetic skin wounds (Wong et al.,
2015). Staining for NETs in wounded and tumor-bearing skin
clearly showed reduced NET formation in the absence of kerati-
nocyte-derived HMGB1 (Figure 3E). We cannot exclude addi-
tional NET-independent effects of keratinocyte-derived
HMGB1 on neutrophil function. Indeed, decreased neutrophil
infiltration in DKer HMGB1 mice is in accordance with the role
of HMGB1 as a cytokine. We hypothesize that HMGB1 critically2698 Cell Reports 29, 2689–2701, November 26, 2019contributes to exceeding the inflamma-
tory threshold by the recruitment of neu-
trophils and the formation of NETs,
thereby creating an inflammatory milieu
that in turn favors NET formation. Howev-
er, the direct and critical involvement of
NETs was apparent from the tumor-pro-tective and accelerated regenerative effect of DNase1 treatment
during early post-wounding stages (Figures 4C and 4E).
NET formation has been documented in murine breast cancer
tumors, and metastatic cancer cells can induce NETs, thereby
promoting cancer dissemination (Park et al., 2016). NET forma-
tion through neutrophil priming has also been shown to favor tu-
mor growth (Demers et al., 2016), together suggesting the impor-
tance of NET formation for cancer. Our study proves that the
initial burst of NET formation caused by epithelial injury in the
skin critically promotes tumor initiation and is mediated by
epithelial-derived HMGB1 release.
Our observations in RDEB patients, in which we demonstrate
the presence of NETs in lesional skin and SCCs (Figure 6A), indi-
cate that these molecular events are relevant to human disease.
We propose that anti-HMGB1, anti-TNF, or anti-NET therapies
might be of particular interest in such patients, as well as in
wound care of diabetic patients suffering from chronic ulcers,
since these therapies could ameliorate wound healing re-
sponses, while limiting the risk of cutaneous tumorigenicity.
Finally, this newly identified role of HMGB1 in mediating tumori-
genicity of wounds through NET formationmight well represent a
signaling cascade that impacts on other barrier tissues where
trauma is linked to tumor formation, such as in lung, liver, or
the intestine, suggesting that HMGB1 targeting or prevention
of NET formation might also be beneficial as a therapy in such
disease conditions.
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LEAD CONTACT AND MATERIALS AVAILABILITY
Further information and requests for resources and reagents may be directed to Esther Hoste (Lead Contact; Esther.Hoste@irc.
vib-ugent.be). Transfer of materials may require a material transfer agreement to be signed.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Mice
HMGB1 ‘floxed’ (Huebener et al., 2014), InvEE (Hobbs et al., 2004), Keratin-5 (K5)-Cre (Tarutani et al., 1997), LysozymeM (LysM)-Cre
(Clausen et al., 1999) and RIPK1D138N (Polykratis et al., 2014) mice have been previously described. InvEEmice weremaintained on a
mixed CBA x C57/Bl6 background and kept heterozygous for the MEK1 transgene. Transgene-negative HMGB1fl/fl littermates were
used as controls. Both female andmale mice of 7 to 18 weeks old were used and nomice died as a direct result of wounding or tumor
formation and mice of the indicated genotype were assigned to groups at random. Mouse studies as well as immunostainings were
performed in a blinded fashion.
Isolation and culture conditions of keratinocytes
Primarymouse keratinocytes were isolated fromHMGB1fl/fl andDKer HMGB1mouse back skin as described previously (Jensen et al.,
2010) and cultured on feeders. Briefly, shaved back skin was isolated, sterilized and floated on trypsin overnight. Epidermis was
separated from the dermis and cultured on confluent feeders. Human keratinocyte cell lines were cultured on feeders. Once kera-
tinocyte cultures reached confluency, a medium switch to keratinocyte serum-free medium (KSFM) containing 30 mg ml-1 bovine
pituitary extract was performed. Conditioned medium from these cultures was isolated after 48 hours.
Study approval
All animal procedures were conducted in accordance with European, national and institutional guidelines and protocols were subject
to local ethical approval by Ghent university Ethical Board (license number: LA 1400091/LA 2400526). All human samples were
collected after informed, written consent and in accordance with Helsinki guidelines. The study protocol was approved by the
Universities of Monterrey and DEBRA Chile.
METHOD DETAILS
Wound healing assays and wound-induced tumor formation
Full-thickness wounds on the back skin of shavedmiceweremade by using an 8mmpunch biopsy needle (Stiefel Instruments) under
analgesia and general anesthesia in 7 to 20 weeks-old aged- and sex-matched transgenic and control littermates. Wound and tumor
sizes were measured every other day by two independent researchers, who were blinded to group allocations. Both female andmale
mice were included and statistical power was calculated by the resource equation. Animals were randomly assigned to treatment
groups and no animals were excluded from experiments. In conditions where mice were treated, animals were intradermally injected
with Box A (250 mg), ethylpyruvate (40 mg/kg), DNase-1 (1000 units), TNF blocking antibody (MP6-XT22 Mab; 100 mg/injection/
mouse), RAGE antagonistic peptide (R&D Systems: 100 mg/injection), or TLR-4 blocking antibody (Novimmune, clone 5E3;
100 mg/injection) in 200 mL PBS, respectively, at time of wounding and at 12, 24 and 36 hours after wounding. Control mice were
injected with equal volumes of PBS or the appropriate IgG control antibody.
Chemical carcinogenesis protocols
For two-stage carcinogenesis, mice of 7 weeks old were shaved and topically treated with 100 nmol DMBA (Sigma-Aldrich), followed
by three times weekly applications of 6 nmol TPA (Sigma-Aldrich) in 200 mL of acetone for 15 weeks. Papillomas and SCCs were
monitored once a week by two independent researchers, who were blinded to group allocations. For complete carcinogenesis,
mice were topically treated with 5 mg DMBA in 200 mL of acetone twice a week for 20 weeks.
Induction of type 1 diabetes by streptozotocin injections
Diabetes induction was performed by multiple low-dose injections of streptozotocin (STZ; Sigma). 5 to 12-week old male mice were
randomized into treatment groups and fasted for 8 hours overnight and injected intraperitoneal with vehicle or STZ (50mg/kg per day,
pH4, dissolved in 0.1 M sodium citrate buffer) for 5 consecutive days. Fed blood glucose levels were measured weekly starting
2 weeks after last injection. Mice with fed glucose levels above 300 mg/dl for 3 consecutive weeks were considered diabetic and
used for further experiments.
Immunofluorescence
Paraffin sections were labeled with rabbit anti-histone-3 citrullinated Ab (H3citr; 1:500; citrulline R2+R8+R17; Abcam ab5103; lot:
543646), goat anti-neutrophil elastase (NE; 1: 500; Santa Cruz SC-9521) or rabbit anti-HMGB1 antibody (1:500; Abcam ab79823
clone EPR 3507) for one hour. As secondary antibodies donkey-anti-goat 488 AlexaFluor (1:2000) and goat-anti-rabbit DyLight
586 (1:2000) were used in combination with Dapi.Cell Reports 29, 2689–2701.e1–e4, November 26, 2019 e2
Immunohistochemistry
Dewaxed paraffin sections were subjected to heat-mediated antigen retrieval (citrate buffer; pH = 6) and labeled with anti-TNF Ab
(R&D Systems; 1:500). Slides were incubated with secondary antibody, followed by avidin-biotin complexes and peroxidase activity
was detected with diaminobutyric acid (DAB) substrate (Vector Laboratories).
Western blotting
Unwounded, wounded or tumor-bearing skin was lysed in buffer containing 10mMTris-HCl at pH 7, 200mMNaCl, 5mMEDTA, 10%
glycerol, 1% NP-40 and supplemented with complete EDTA-free Protease Inhibitor Cocktail Tablets (Roche Diagnostics) and Phos-
pho-STOP Phosphatase Inhibitor Cocktail Tablets (RocheDiagnostics) and subsequently homogenized using Precellys beads. 20 mg
of protein was separated on 15%SDS-PAGE and transferred to a nitrocellulosemembrane. Immunoblotting was performedwith rab-
bit anti-histone-3 citrullinated Ab (citrulline R2+R8+R17; GR314058-2; ab 5103; 1:1000; Abcam), rabbit anti-HMGB1 (1:500; Abcam),
mouse anti-actin (1:10 000; BioConnect) antibodies and the appropriate HRP-coupled secondary antibodies (GE Healthcare).
Detection was performed with the Western Lightning chemiluminescence reagent plus kit (PerkinElmer).
Flow cytometry
Immunophenotyping of wounded skin was performed on single-cell suspensions derived frommouse skin following trypsin digestion
for 1 hour at 37C and subsequent digestion with collagenase type 1 (1,25 mg/ml) (GIBCO), type 2 (0,5 mg/ml) (Sigma) and type 4
(0,5 mg/ml) (Sigma) for 30 to 45 min. Cells were stained with the following fluorochrome-linked antibodies: CD45-PE, CD11b-
BV421, Ly6G-APC, CD64-BV711, anti-histone-3 citrullinated (citrulline R2+R8+R17; ab 5103; Abcam), L/D eFluor780 (eBiosciences)
and Fc receptor-blocking antibody CD16/CD32 (clone 2.4G2, BD Biosciences). Prior to measuring, counting beads (Life Technolo-
gies) were added to the cells. Flow sorting of live mouse keratinocytes was performed after staining for integrin alpha-6 (BD
BioScienes) on single-cell suspensions derived from epidermis isolated as previously described (Jensen et al., 2010). Measurements
were performed on a BD Fortessa cytometer and analyzed using FlowJo software (Tree Star).
Recombinant mHMGB1 A-box expression and purification
pGEX-6P-2-mHMGB1 A-box plasmid was transformed in E.coli strain BL21(DE3). Exponentially growing cultures were induced with
0.5 mM isopropyl-b-D-thiogalactopyranoside and incubated at 20C for 4h. Cell pellets were resuspended in buffer A [10 mM
Na2HPO4 pH 7.4, 500 mM NaCl, 0.5 mM DTT, DNase 1 (1 mg/100 mL, Roche Diagnostics) and complete EDTA-free Protease Inhib-
itor Cocktail Tablets (Roche Diagnostics)], and lysed by sonication. Insoluble proteins were removed by centrifugation. The super-
natant was incubated with DEAE resin (GE Healthcare) pre-equilibrated with buffer A. The DEAE flow-through fraction was applied
to a glutathione Sepharose 4FF column (GE Healthcare) pre-equilibrated with buffer B (PBS pH 7.4). GST-tagged mHMGB1 A-box
was eluted from the column with buffer C (50 mM Tris-HCl pH 8.5, 300 mMNaCl, 40 mM reduced glutathione). Elution fractions con-
taining GST- mHMGB1 A-box were pooled and desalted against buffer D (50 mM Tris-HCl pH 7.0, 150 mMNaCl, 1 mM EDTA, 1 mM
DTT). The GST- mHMGB1 A-box fusion protein was digested with the PreScission Protease (GE Healthcare) to clip off GST. The di-
gested sample was run on a glutathione Sepharose 4B column (GE Healthcare) pre-equilibrated with buffer B for removal of the GST-
tag and the PreScission Protease. Flow-through fractions containing mHMGB1 A-box, were pooled. After a buffer exchange step to
buffer E (40 mM HEPES pH 7.4), the purified recombinant mHMGB1 A-box protein was applied to SP Sepharose FF (GE Healthcare)
and eluted in buffer F (2x PBS pH 7.4). The elution fractions containing mHMGB1 A-box were pooled and diluted to 1x PBS pH 7.4.
The purity of the fractions was checked by means of SDS-PAGE.
Primary keratinocyte cultures and scratch-wound assays
Primary keratinocytes obtained from DKer HMGB1 and control mice were obtained as previously described (Jensen et al., 2010).
Scratching was performed on confluent keratinocyte cultures and wound closure was monitored by repetitive imaging.
RNA isolation and qPCR
RNA was isolated from tissues by column purification (QIAGEN RNeasy mini). Following reverse transcription, qPCR analysis was
performed using primer-pairs against Cxcl-2 (Fp: CAGACTCCAGCCACACTTCA; Rp: CACATCAAGCTCTGGATGTT), RANTES
(Fp: CACTTGCTGCTGGTGTAGAAA; Rp: CCCTCACCATCATCCTCACT) and normalized to GAPDH (Fp: AACATCAAATGGGG
TGAGGCC; Rp: GTTGTCATGGATGACCTTGGC).
Cytokine measurements
HMGB1 levels in serum and conditioned medium were determined by ELISA according to the manufacturer’s instructions (Tecan).
Serum levels of TNF, IL-6 and IL-8 were determined by magnetic bead-based multiplex assay (eBioSciences).
RNA sequencing and bioinformatics
RNA (RIN > 8, as determined by Bioanalyzer 2100, Agilent) was isolated from live keratinocytes sorted fromHMGB1fl/fl (n = 4) andDKer
HMGB1 (n = 4) mice. Libraries were constructed using the Illumina TruSeq RNA Preparation Kit. RNA sequencing was performed
at the VIB Nucleomics Core using HiSeq4000 SR50 (Illumina). The preprocessing of the RNA sequencing data was done bye3 Cell Reports 29, 2689–2701.e1–e4, November 26, 2019
Trimmomatic. The adapters were cut off, and reads were trimmedwhen the quality dropped below 20. Reads with a length < 35 were
discarded. All samples passed quality control based on the results of FastQC. Reads were mapped to the mouse reference genome
(mm10) via Tophat2 and counted via HTSeqCount. Samples were subsequently analyzed using R/Bioconductor, and the R package
limma was used to normalize the data and to perform differential expression analysis. Benjamini-Hochberg was used to adjust the p
values for multiple testing. For the analysis of DE genes, we applied limma-treat with a stringency level where the adjusted p value
needs to be lower than 0.05 and the log2FC lower than 1 or higher than 1. For the heatmap we scaled the normalized log2 expres-
sion values per gene by calculating the mean expression per gene and then subtracting that mean value of each expression value.
Isolation of polymorphonuclear leukocytes
20 mL of heparinized blood was isolated from each healthy donor. 15 mL of PBS without calcium and magnesium (Thermo Fisher
Scientific) was added and the suspension was applied on 15ml of Ficoll (Bio-Rad). Cells were centrifuged at 1400 rpm for 30 min
at room temperature and suspension above the buffy coat removed. The white layer containing PMNs was collected and erythro-
cytes were removed by short cycles of hypotonic lysis with deionized water.
Live Cell Imaging
Human PMN cultures seeded in an 8 well chamber (iBidi) and supplemented with 2,5 mMSytox Green (Thermo Fischer Scientific) and
1 mMHoechst (Thermo Fischer Scientific) were incubated with conditioned medium from human keratinocyte cultures or stimulated
with TNF (1 mg/ml) or ionomycin (1 mg/ml). Live cell imaging was performed on an Axio Observer.Z1 (Zeiss, Germany) equipped with a
CSU-X1 spinning-disk head (Yokogawa Corporation of America) and stage top incubator (5%CO2, 37
C). DIC and fluorescence Im-
ages were acquired with a plan Apo 20x/0.8 objective every 10minutes for a period of 24 hours using an EMCCD ImageMX2 camera
(Hamamatsu). Sytox Green and Hoechst were excited with respectively a 405 and 488 nm diode laser. Image processing and movie
editing was carried out in ImageJ (NIH) and data analysis was done with Volocity 6.3.0 (Perkin Elmer).
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical details of experiments can be found in the figure legends and Results sections. At least four replicates were generally used
for each experimental condition for in vitro and ex vivo experiments. For in vivo experiments, at least 7 mice were used per group and
experimental sample sizeswere determined on the basis of prior power calculations. Additional experimentsmay be performedwhen
larger variation in data was observed, and data were pooled for analysis.
DATA AND CODE AVAILABILITY
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